Antidiabetic Thiazolidinediones Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1062695
  • May 2021
  • Pharmaceuticals
  • 139 Pages
The Antidiabetic Thiazolidinediones market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Antidiabetic Thiazolidinediones market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Eli Lilly, Merck and Co., AstraZeneca, GlaxoSmithKline, Sanofi, Takeda Pharmaceuticals, Novo Nordisk, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Limited, Solco Healthcare U.S., LLC, Macleods Pharmaceuticals Limited, PuraCap Pharmaceutical LLC
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Antidiabetic Thiazolidinediones market along with their effects over the forecast period. Similarly, according to the region Antidiabetic Thiazolidinediones market research report includes the study of opportunities available in the market situation.

The Antidiabetic Thiazolidinediones market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Antidiabetic Thiazolidinediones Market:
The Antidiabetic Thiazolidinediones market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Eli Lilly, Merck and Co., AstraZeneca, GlaxoSmithKline, Sanofi, Takeda Pharmaceuticals, Novo Nordisk, Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Limited, Solco Healthcare U.S., LLC, Macleods Pharmaceuticals Limited, PuraCap Pharmaceutical LLC

Antidiabetic Thiazolidinediones Market Segmentation Analysis:
By Type
Rosiglitazone
Pioglitazone
End User
Hospital
Clinic
Others


Global Antidiabetic Thiazolidinediones Market Segmentation by Regions:
In regional analysis, Antidiabetic Thiazolidinediones market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Antidiabetic Thiazolidinediones market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Antidiabetic Thiazolidinediones Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Antidiabetic Thiazolidinediones Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Antidiabetic Thiazolidinediones Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Antidiabetic Thiazolidinediones Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Antidiabetic Thiazolidinediones Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Antidiabetic Thiazolidinediones market, according to the key region.
  • To study the Antidiabetic Thiazolidinediones market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Antidiabetic Thiazolidinediones market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Antidiabetic Thiazolidinediones research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Antidiabetic Thiazolidinediones market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Antidiabetic Thiazolidinediones market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Antidiabetic Thiazolidinediones market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Antidiabetic Thiazolidinediones market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Antidiabetic Thiazolidinediones market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Bristol-Myers Squibb
  • Pfizer
  • Boehringer Ingelheim
  • Eli Lilly
  • Merck and Co.
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Takeda Pharmaceuticals
  • Novo Nordisk
  • Mylan Pharmaceuticals Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Aurobindo Pharma Limited
  • Solco Healthcare U.S., LLC
  • Macleods Pharmaceuticals Limited
  • PuraCap Pharmaceutical LLC
  • Rosiglitazone
  • Pioglitazone
  • Hospital
  • Clinic
  • Others

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Antidiabetic Thiazolidinediones Market Snapshot
          2.1.1. Global Antidiabetic Thiazolidinediones Market By Type,2019
               2.1.1.1.Rosiglitazone
               2.1.1.2.Pioglitazone
          2.1.2. Global Antidiabetic Thiazolidinediones Market By End User,2019
               2.1.2.1.Hospital
               2.1.2.2.Clinic
               2.1.2.3.Others
          2.1.3. Global Antidiabetic Thiazolidinediones Market By End-use,2019
          2.1.4. Global Antidiabetic Thiazolidinediones Market By Geography,2019

3. Global Antidiabetic Thiazolidinediones Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028

5. Global Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By End User, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By End User, 2020
     5.2. Global Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028

6. Global Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028

7. Global Antidiabetic Thiazolidinediones Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Antidiabetic Thiazolidinediones Market Analysis, 2018 – 2028 
          7.2.1. North America Antidiabetic Thiazolidinediones Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028
          7.2.4. North America Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Antidiabetic Thiazolidinediones Market Analysis, 2018 – 2028 
          7.3.1.  Europe Antidiabetic Thiazolidinediones Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028
          7.3.4. Europe Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Antidiabetic Thiazolidinediones Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Antidiabetic Thiazolidinediones Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028
          7.4.4. Asia Pacific Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Antidiabetic Thiazolidinediones Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Antidiabetic Thiazolidinediones Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028
          7.5.4. Latin America Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Antidiabetic Thiazolidinediones Market Analysis, 2018 – 2028 
          7.6.1.  MEA Antidiabetic Thiazolidinediones Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Antidiabetic Thiazolidinediones Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Antidiabetic Thiazolidinediones Market Size (US$), By End User, 2018 – 2028
          7.6.4. MEA Antidiabetic Thiazolidinediones Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Antidiabetic Thiazolidinediones Providers
        8.4.1 Bristol-Myers Squibb
                8.4.1.1 Business Description
                8.4.1.2 Bristol-Myers Squibb Geographic Operations
                8.4.1.3 Bristol-Myers Squibb Financial Information
                8.4.1.4 Bristol-Myers Squibb Product Positions/Portfolio
                8.4.1.5 Bristol-Myers Squibb Key Developments
        8.4.2 Pfizer
                8.4.2.1 Business Description
                8.4.2.2 Pfizer Geographic Operations
                8.4.2.3 Pfizer Financial Information
                8.4.2.4 Pfizer Product Positions/Portfolio
                8.4.2.5 Pfizer Key Developments
        8.4.3 Boehringer Ingelheim
                8.4.3.1 Business Description
                8.4.3.2 Boehringer Ingelheim Geographic Operations
                8.4.3.3 Boehringer Ingelheim Financial Information
                8.4.3.4 Boehringer Ingelheim Product Positions/Portfolio
                8.4.3.5 Boehringer Ingelheim Key Developments
        8.4.4 Eli Lilly
                8.4.4.1 Business Description
                8.4.4.2 Eli Lilly Geographic Operations
                8.4.4.3 Eli Lilly Financial Information
                8.4.4.4 Eli Lilly Product Positions/Portfolio
                8.4.4.5 Eli Lilly Key Developments
        8.4.5 Merck and Co.
                8.4.5.1 Business Description
                8.4.5.2 Merck and Co. Geographic Operations
                8.4.5.3 Merck and Co. Financial Information
                8.4.5.4 Merck and Co. Product Positions/Portfolio
                8.4.5.5 Merck and Co. Key Developments
        8.4.6 AstraZeneca
                8.4.6.1 Business Description
                8.4.6.2 AstraZeneca Geographic Operations
                8.4.6.3 AstraZeneca Financial Information
                8.4.6.4 AstraZeneca Product Positions/Portfolio
                8.4.6.5 AstraZeneca Key Developments
        8.4.7 GlaxoSmithKline
                8.4.7.1 Business Description
                8.4.7.2 GlaxoSmithKline Geographic Operations
                8.4.7.3 GlaxoSmithKline Financial Information
                8.4.7.4 GlaxoSmithKline Product Positions/Portfolio
                8.4.7.5 GlaxoSmithKline Key Developments
        8.4.8 Sanofi
                8.4.8.1 Business Description
                8.4.8.2 Sanofi Geographic Operations
                8.4.8.3 Sanofi Financial Information
                8.4.8.4 Sanofi Product Positions/Portfolio
                8.4.8.5 Sanofi Key Developments
        8.4.9 Takeda Pharmaceuticals
                8.4.9.1 Business Description
                8.4.9.2 Takeda Pharmaceuticals Geographic Operations
                8.4.9.3 Takeda Pharmaceuticals Financial Information
                8.4.9.4 Takeda Pharmaceuticals Product Positions/Portfolio
                8.4.9.5 Takeda Pharmaceuticals Key Developments
        8.4.10 Novo Nordisk
                8.4.10.1 Business Description
                8.4.10.2 Novo Nordisk Geographic Operations
                8.4.10.3 Novo Nordisk Financial Information
                8.4.10.4 Novo Nordisk Product Positions/Portfolio
                8.4.10.5 Novo Nordisk Key Developments
        8.4.11 Mylan Pharmaceuticals Inc.
                8.4.11.1 Business Description
                8.4.11.2 Mylan Pharmaceuticals Inc. Geographic Operations
                8.4.11.3 Mylan Pharmaceuticals Inc. Financial Information
                8.4.11.4 Mylan Pharmaceuticals Inc. Product Positions/Portfolio
                8.4.11.5 Mylan Pharmaceuticals Inc. Key Developments
        8.4.12 Teva Pharmaceuticals USA, Inc.
                8.4.12.1 Business Description
                8.4.12.2 Teva Pharmaceuticals USA, Inc. Geographic Operations
                8.4.12.3 Teva Pharmaceuticals USA, Inc. Financial Information
                8.4.12.4 Teva Pharmaceuticals USA, Inc. Product Positions/Portfolio
                8.4.12.5 Teva Pharmaceuticals USA, Inc. Key Developments
        8.4.13 Aurobindo Pharma Limited
                8.4.13.1 Business Description
                8.4.13.2 Aurobindo Pharma Limited Geographic Operations
                8.4.13.3 Aurobindo Pharma Limited Financial Information
                8.4.13.4 Aurobindo Pharma Limited Product Positions/Portfolio
                8.4.13.5 Aurobindo Pharma Limited Key Developments
        8.4.14 Solco Healthcare U.S., LLC
                8.4.14.1 Business Description
                8.4.14.2 Solco Healthcare U.S., LLC Geographic Operations
                8.4.14.3 Solco Healthcare U.S., LLC Financial Information
                8.4.14.4 Solco Healthcare U.S., LLC Product Positions/Portfolio
                8.4.14.5 Solco Healthcare U.S., LLC Key Developments
        8.4.15 Macleods Pharmaceuticals Limited
                8.4.15.1 Business Description
                8.4.15.2 Macleods Pharmaceuticals Limited Geographic Operations
                8.4.15.3 Macleods Pharmaceuticals Limited Financial Information
                8.4.15.4 Macleods Pharmaceuticals Limited Product Positions/Portfolio
                8.4.15.5 Macleods Pharmaceuticals Limited Key Developments
        8.4.16 PuraCap Pharmaceutical LLC
                8.4.16.1 Business Description
                8.4.16.2 PuraCap Pharmaceutical LLC Geographic Operations
                8.4.16.3 PuraCap Pharmaceutical LLC Financial Information
                8.4.16.4 PuraCap Pharmaceutical LLC Product Positions/Portfolio
                8.4.16.5 PuraCap Pharmaceutical LLC Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Antidiabetic Thiazolidinediones Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Antidiabetic Thiazolidinediones Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Antidiabetic Thiazolidinediones Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Antidiabetic Thiazolidinediones Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Antidiabetic Thiazolidinediones Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Antidiabetic Thiazolidinediones Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Antidiabetic Thiazolidinediones Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Antidiabetic Thiazolidinediones Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Antidiabetic Thiazolidinediones Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Antidiabetic Thiazolidinediones Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Antidiabetic Thiazolidinediones Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Antidiabetic Thiazolidinediones Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Antidiabetic Thiazolidinediones Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Antidiabetic Thiazolidinediones Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Antidiabetic Thiazolidinediones Market Revenue, By End User, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Antidiabetic Thiazolidinediones Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Antidiabetic Thiazolidinediones: Market Segmentation 
FIG. 2 Global Antidiabetic Thiazolidinediones Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Antidiabetic Thiazolidinediones Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Antidiabetic Thiazolidinediones Market, By End User, 2019 (US$ Mn) 
FIG. 6 Global Antidiabetic Thiazolidinediones Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Antidiabetic Thiazolidinediones Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Antidiabetic Thiazolidinediones Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Antidiabetic Thiazolidinediones Providers, 2019
FIG. 11 Global Antidiabetic Thiazolidinediones Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Antidiabetic Thiazolidinediones Market Revenue Contribution, By End User, 2019 & 2028 (Value %) 
FIG. 13 Global Antidiabetic Thiazolidinediones Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Antidiabetic Thiazolidinediones Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Antidiabetic Thiazolidinediones Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Antidiabetic Thiazolidinediones Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Antidiabetic Thiazolidinediones Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Antidiabetic Thiazolidinediones Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Antidiabetic Thiazolidinediones market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Antidiabetic Thiazolidinediones Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Antidiabetic Thiazolidinediones Market Value, By Segment1, 2018 – 2028
TABLE  North America Antidiabetic Thiazolidinediones Market Value, By Segment2, 2018 – 2028
TABLE  North America Antidiabetic Thiazolidinediones Market Value, By Country, 2018 – 2028
TABLE  Europe Antidiabetic Thiazolidinediones Market Value, By Segment1, 2018 – 2028
TABLE  Europe Antidiabetic Thiazolidinediones Market Value, By Segment2, 2018 – 2028
TABLE  Europe Antidiabetic Thiazolidinediones Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Antidiabetic Thiazolidinediones Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Antidiabetic Thiazolidinediones Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Antidiabetic Thiazolidinediones Market Value, By Country, 2018 – 2028
TABLE  Latin America Antidiabetic Thiazolidinediones Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Antidiabetic Thiazolidinediones Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Antidiabetic Thiazolidinediones Market Value, By Country, 2018 – 2028
TABLE  MEA Antidiabetic Thiazolidinediones Market Value, By Segment1, 2018 – 2028
TABLE  MEA Antidiabetic Thiazolidinediones Market Value, By Segment2, 2018 – 2028
TABLE  MEA Antidiabetic Thiazolidinediones Market Value, By Country, 2018 – 2028
TABLE  Bristol-Myers Squibb: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Pfizer: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Boehringer Ingelheim: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Eli Lilly: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck and Co.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Takeda Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novo Nordisk: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mylan Pharmaceuticals Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Teva Pharmaceuticals USA, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Aurobindo Pharma Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Solco Healthcare U.S., LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Macleods Pharmaceuticals Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  PuraCap Pharmaceutical LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Antidiabetic Thiazolidinediones Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Antidiabetic Thiazolidinediones Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Antidiabetic Thiazolidinediones Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Antidiabetic Thiazolidinediones Market, By Geography, 2019 (US$ Mn)
FIG.  Global Antidiabetic Thiazolidinediones Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Antidiabetic Thiazolidinediones Providers, 2016
FIG.  Global Antidiabetic Thiazolidinediones Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Pioglitazone Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Antidiabetic Thiazolidinediones Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Clinic Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Antidiabetic Thiazolidinediones Market Value, 2018 – 2028, (US$ Mn)